Amitriptyline Should Be Used Over Dosulepin (Prothiaden) for Headache Prophylaxis
Amitriptyline is the recommended first-line tricyclic antidepressant for migraine prophylaxis, with strong guideline support and established efficacy, while dosulepin (Prothiaden) lacks evidence-based recommendations in headache management guidelines.
Evidence-Based Recommendation
The most recent and authoritative guidelines consistently identify amitriptyline as a first-line prophylactic agent for migraine headaches. The 2025 American College of Physicians guideline 1 and the 2002-2003 U.S. Headache Consortium guidelines 2, 3 all specifically recommend amitriptyline at 30-150 mg/day as a first-line preventive medication with good evidence for efficacy.
Notably, dosulepin (Prothiaden) does not appear in any major headache prophylaxis guidelines reviewed, indicating it is not an evidence-based choice for this indication.
Dosing Strategy for Amitriptyline
Starting Dose
- Begin with 10-25 mg nightly 4, 5
- For outpatients, the FDA label recommends starting at 75 mg/day in divided doses, but clinical practice and recent evidence support much lower starting doses 6
Titration Approach
- Increase by 10-25 mg every 3-5 days as tolerated 4
- Target dose: 30-150 mg/day for migraine prophylaxis 2, 3
- Most patients respond to 10-50 mg daily in real-world practice 6
Important Clinical Finding
A 2016 retrospective study 6 found that low doses (10-25 mg daily) were effective in 75% of patients treated in specialty headache practice, with 85% still taking the medication at follow-up. This challenges the traditional higher dosing used in older clinical trials and suggests better tolerability and persistence with lower doses.
Efficacy Evidence
Migraine Prophylaxis
- Amitriptyline has consistent evidence from multiple randomized controlled trials 2
- A large placebo-controlled trial 7 showed significant improvement at 8 weeks (p=0.018)
- Particularly effective for chronic daily headache (CDH): 46% achieved ≥50% improvement at 16 weeks vs 9% with placebo (p=0.043) 7
Pediatric Population
- Effective at 1 mg/kg/day in children 8
- 84.2% reported overall improvement with minimal side effects
- Reduced headache frequency from 17.1 to 9.2 days/month
Safety Considerations
Common Adverse Effects
- Daytime fatigue (most common, 11% in real-world practice) 6
- Sedation, dry mouth, urinary hesitancy 4
- Weight gain 3
Contraindications and Cautions
- Cardiovascular disease: Monitor closely; can cause arrhythmias, sinus tachycardia, prolonged conduction 5
- Angle-closure glaucoma: Even average doses may precipitate an attack 5
- Urinary retention history: Use with caution 5
- Pregnancy Category C: Crosses placenta; use only if benefit justifies risk 5
- Elderly patients: Start with 10 mg three times daily plus 20 mg at bedtime 5
Drug Interactions
- Enhances alcohol and CNS depressant effects 5
- May block antihypertensive action of guanethidine 5
- Caution with thyroid medication (enhances response) 5
Clinical Algorithm for Selection
When to Choose Amitriptyline:
- Mixed migraine and tension-type headache (superior to propranolol in this population) 2, 3
- Comorbid insomnia (sedating properties beneficial) 4
- Comorbid depression/anxiety 3
- Chronic daily headache (strong evidence) 7
When to Avoid:
- Cardiovascular disease without close monitoring
- Angle-closure glaucoma
- Significant anticholinergic sensitivity
- Pregnancy (unless benefit clearly outweighs risk)
Comparison with Other First-Line Agents
The 2002 guidelines 2 establish amitriptyline alongside:
- Beta-blockers (propranolol 80-240 mg/day, timolol 20-30 mg/day)
- Anticonvulsants (divalproex sodium 500-1500 mg/day)
Amitriptyline is specifically superior for:
- Patients with mixed migraine and tension-type headache 2, 3
- Those requiring sedation for comorbid insomnia
- Chronic daily headache patterns 7
Monitoring and Duration
- Onset of analgesic effect: Usually earlier than antidepressant effect, but may take up to 30 days for full therapeutic benefit 4
- Adequate trial period: 2-3 months before determining efficacy 3
- Maintenance therapy: Continue for 3 months or longer after achieving improvement 5
- Plasma level monitoring: Consider in elderly patients or those with suspected toxicity/non-compliance 5
Common Pitfall to Avoid
Do not start with traditional antidepressant doses (75-150 mg). Real-world evidence 6 demonstrates that most patients respond to and tolerate 10-50 mg daily much better, with improved medication persistence (85% still taking at follow-up). Starting too high increases discontinuation due to side effects without improving efficacy for headache prophylaxis.